Burlington, Ontario

Michael A. Jenkins, President & CEO of The Jenex  Corporation  (the "Corporation") is pleased to announce that on March 15, 2006, the Corporation completed the previously announced non-brokered private placement for total gross proceeds of $190,000.

The private placement raised gross proceeds of $190,000 and resulted in the issuance of 1,000,000 units at a price $0.19 per unit to  investors . Each unit is comprised of one (1) common share of the Corporation and 0.19 of a non-transferable share purchase warrant (190,000 whole warrants in total). Each whole warrant entitles the holder thereof to purchase one (1) additional common share of the Corporation at a price of $0.30 per share for a period of two years commencing from the closing date.  In connection with the foregoing, the Corporation paid an agent finders fee to Kingsdale Capital Markets Inc., of $7,438 in cash and 78,300 warrants, on the same terms as the warrants issued to investors.

About The Jenex Corporation

Headquartered in Burlington, Ontario, the Corporation owns a patented Thermal Therapy Technology. Patents in the United States, Canada, Australia, and Europe protect the Technology. The Corporation is currently preparing for the launch of intercept^CS™ in the Canadian market in first quarter 2006. intercept^CS is the first product proven and approved to prevent cold sores. Jenex has been approved to market intercept^CS in Canada with its approved claim, "For prevention and relief of the symptoms of herpes labialis (cold sores), such as blistering, lesions, inflammation, and discomfort. Also helps alleviate the embarrassment that is typically associated with herpes labialis (cold sore) outbreaks".